QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
NASDAQ:DNLI

Denali Therapeutics News Headlines

$31.42
-3.42 (-9.82%)
(As of 01/18/2022 04:00 PM ET)
Add
Compare
Today's Range
$31.35
$33.94
50-Day Range
$31.42
$52.16
52-Week Range
$30.25
$83.98
Volume
785,089 shs
Average Volume
828,698 shs
Market Capitalization
$3.84 billion
P/E Ratio
224.44
Dividend Yield
N/A
Beta
1.75
Get Denali Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Denali Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

DNLI
News Sentiment

0.31

0.33

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

DNLI Articles
This Week

14

1

DNLI Articles
Average Week



Denali Therapeutics (NASDAQ:DNLI) News Headlines Today

SourceHeadline
MarketBeat logoDenali Therapeutics (NASDAQ:DNLI) Shares Down 8.2%
americanbankingnews.com - January 18 at 1:50 PM
MarketBeat logoComparing Achilles Therapeutics (NASDAQ:ACHL) and Denali Therapeutics (NASDAQ:DNLI)
americanbankingnews.com - January 16 at 12:18 PM
benzinga.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Denali Therapeutics Inc. - DNLI
benzinga.com - January 13 at 8:19 PM
finance.yahoo.com logoWhy Denali Therapeutics Stock Is Sinking This Week
finance.yahoo.com - January 13 at 8:19 PM
msn.com logoFDA Places Clinical Hold On Denali's Alzheimer's Potential Program
msn.com - January 13 at 1:34 PM
nasdaq.com logoRelative Strength Alert For Denali Therapeutics
nasdaq.com - January 13 at 1:34 PM
finance.yahoo.com logoDenali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure
finance.yahoo.com - January 13 at 1:34 PM
seekingalpha.com logoDenali Therapeutics falls on clinical hold for Alzheimer’s candidate
seekingalpha.com - January 13 at 8:34 AM
finance.yahoo.com logoDenali Therapeutics Announces FDA Clinical Hold on DNL919 Investigational New Drug (IND) Application
finance.yahoo.com - January 13 at 8:34 AM
MarketBeat logoDenali Therapeutics (NASDAQ:DNLI) Sets New 52-Week Low at $38.51
americanbankingnews.com - January 13 at 3:34 AM
MarketBeat logoDenali Therapeutics (NASDAQ:DNLI) Stock Price Down 4.3%
americanbankingnews.com - January 12 at 1:42 PM
nasdaq.com logoDenali Therapeutics Inc Shares Close in on 52-Week Low - Market Mover
nasdaq.com - January 9 at 1:10 AM
insidertrades.com logoDenali Therapeutics Inc. (NASDAQ:DNLI) CFO Sells $99,568.75 in Stock
insidertrades.com - January 7 at 7:10 PM
MarketBeat logoDenali Therapeutics Inc. (NASDAQ:DNLI) Insider Carole Ho Sells 2,845 Shares
americanbankingnews.com - January 7 at 7:10 PM
MarketBeat logoInsider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) COO Sells 2,846 Shares of Stock
americanbankingnews.com - January 7 at 7:10 PM
MarketBeat logoMorgan Stanley Trims Denali Therapeutics (NASDAQ:DNLI) Target Price to $91.00
americanbankingnews.com - January 7 at 3:24 PM
nasdaq.com logoDenali Therapeutics Inc. Common Stock (DNLI)
nasdaq.com - January 7 at 9:18 AM
insidertrades.com logoInsider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 10,980 Shares of Stock
insidertrades.com - December 31 at 12:15 AM
MarketBeat logoDenali Therapeutics (NASDAQ:DNLI) Shares Down 4.7%
americanbankingnews.com - December 27 at 12:20 PM
MarketBeat logoDenali Therapeutics (NASDAQ:DNLI) Trading Down 4.7%
americanbankingnews.com - December 27 at 12:20 PM
finance.yahoo.com logoDo Hedge Funds Love Denali Therapeutics Inc. (DNLI)?
finance.yahoo.com - December 17 at 7:09 PM
finanznachrichten.de logoFinancialNewsMedia.com: Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
finanznachrichten.de - November 23 at 9:32 AM
ca.finance.yahoo.com logoDenali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commercialize DNL593 (PTV:PGRN)
ca.finance.yahoo.com - November 17 at 8:38 AM
finance.yahoo.com logoDenali (DNLI) Stock Up Despite Wider-Than-Expected Q3 Loss
finance.yahoo.com - November 8 at 2:56 PM
finance.yahoo.com logoShould You Now Liquidate Your Denali Therapeutics (DNLI) Position?
finance.yahoo.com - November 8 at 2:56 PM
finance.yahoo.com logoDenali Therapeutics Inc. (DNLI) Reports Q3 Loss, Misses Revenue Estimates
finance.yahoo.com - November 4 at 9:31 PM
finance.yahoo.com logoDenali Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
finance.yahoo.com - November 4 at 4:31 PM
finance.yahoo.com logoDenali Therapeutics (NASDAQ:DNLI) shareholder returns have been impressive, earning 206% in 3 years
finance.yahoo.com - November 4 at 9:13 AM
finance.yahoo.com logoDenali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
finance.yahoo.com - October 28 at 6:20 PM
finance.yahoo.com logoDenali Therapeutics Insider Trades $500K In Company Stock
finance.yahoo.com - October 7 at 3:14 PM
finance.yahoo.com logoDenali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)
finance.yahoo.com - October 7 at 8:51 AM
finance.yahoo.com logoDenali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting
finance.yahoo.com - September 29 at 7:00 PM
finance.yahoo.com logoDenali Therapeutics Appoints Katie Peng as Chief Commercial Officer
finance.yahoo.com - September 27 at 10:22 AM
finance.yahoo.com logoOppenheimer Says There’s Room for Over 50% Gains in These 3 Stocks
finance.yahoo.com - September 26 at 11:16 PM
finance.yahoo.com logoDenali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS
finance.yahoo.com - September 9 at 3:54 PM
benzinga.com logoPresident And CEO Of Denali Therapeutics Sold $1.00 Million In Stock
benzinga.com - September 5 at 11:42 PM
finance.yahoo.com logoDenali Therapeutics Inc (DNLI) President and CEO Ryan J. Watts Sold $1 million of Shares
finance.yahoo.com - September 3 at 5:18 PM
finance.yahoo.com logoDenali Therapeutics Inc. (DNLI) Up 5.7% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - September 3 at 5:18 PM
finance.yahoo.com logoDenali Therapeutics Inc. (NASDAQ:DNLI) Analysts Are Reducing Their Forecasts For This Year
finance.yahoo.com - August 6 at 7:38 AM
finance.yahoo.com logoIs Denali Therapeutics Inc.'s (NASDAQ:DNLI) Stock Price Struggling As A Result Of Its Mixed Financials?
finance.yahoo.com - August 5 at 9:53 AM
finance.yahoo.com logoWill Denali Therapeutics Inc. (DNLI) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - July 30 at 7:48 PM
finance.yahoo.com logoDenali's Brain-Penetrant Enzyme Therapy Shows Durable Effect With CNS Impact In Hunter Syndrome
finance.yahoo.com - July 26 at 3:03 PM
finance.yahoo.com logoDenali Therapeutics Stock Crashes; Why Investors Are Questioning Its Entire Pipeline
finance.yahoo.com - July 26 at 3:03 PM
finance.yahoo.com logoWhy Denali Therapeutics Stock Is Sinking Today
finance.yahoo.com - July 26 at 3:03 PM
finance.yahoo.com logoDenali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)
finance.yahoo.com - July 25 at 1:21 PM
nasdaq.com logoDenali Therapeutics is Now Oversold (DNLI)
nasdaq.com - July 23 at 1:50 PM
nasdaq.com logoFirst Week of DNLI March 2022 Options Trading
nasdaq.com - July 16 at 6:22 PM
nasdaq.com logoDenali Therapeutics Breaks Below 200-Day Moving Average - Notable for DNLI
nasdaq.com - July 15 at 6:00 PM
finance.yahoo.com logoDenali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021
finance.yahoo.com - July 15 at 1:00 PM
finance.yahoo.com logoWhere Do Hedge Funds Stand On Denali Therapeutics Inc. (DNLI)?
finance.yahoo.com - July 12 at 8:07 PM
Get Denali Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.